December 2, 2023
|
|
|
In recent years, the discourse around medical cannabis and its derivatives, notably CBD (cannabidiol), has transcended the once-taboo realm, gaining momentum as a potential alternative treatment for chronic pain and various ailments. The global landscape is witnessing shifts in legislative stances toward cannabis, from the reclassification by the UN Commission on Narcotic Drugs to Thailand's progressive strides in legalizing cultivation and usage.
Thailand's cannabis evolution: A Legal paradigm shift Johan Mohamad (pix), CEO of Hemptech Asia who was presenting at Healthcare Diverse Careers - Conference and Exhibition shed light on Thailand's groundbreaking move in June 2022, removing cannabis from the narcotics list, opening avenues for cultivation, sales, and legal consumption. "This pivotal step paved the way for exploring the therapeutic potential of cannabinoids, primarily CBD, devoid of the psychoactive 'stoned' effects associated with THC (tetrahydrocannabinol). Cannabinoids and pain management The distinction between industrial hemp and medical cannabis emerges as a critical factor. Hemp, derived from the sativa plant, primarily focuses on extracting cannabinoids from the flower, while medical cannabis, notably Sativa, is tailored for chronic patient care, boasting higher CBD content and targeted therapeutic effects. Johan emphasized CBD's role in addressing various conditions, from Alzheimer's to anxiety, tapping into the endocannabinoid system discovered by Dr John W. Huffman in 1994. "The significance of this system in sync with CBD's interaction with CB1 and CB2 receptors underscores its potential in alleviating pain, autoimmune diseases like multiple sclerosis, and aiding cancer-related discomfort. "My son received a sarcoma diagnosis, prompting me to explore alternative treatments like cannabis oil. When doctors advised us that he had only two weeks to live due to stage 4 sarcoma, I began advocating for cannabis use in our region. Initially sourcing it from illegal farmers in the Philippines, Indonesia, and Thailand, as it wasn't legally available anywhere. Despite this, it provided relief, and over three years, it extended his life. Remarkably, he became one of the healthiest children at the HKL Cancer Department among 200 others. "Unlike the other kids undergoing chemotherapy who would fall asleep, he remained awake. I observed that the oil improved his appetite, boosted his immune system, and rekindled his interest in eating. Expert opinions from doctors in the United States, France, and Italy highlighted the rarity of his case; only two kids worldwide experienced sarcoma that year, one in Italy and my son in Malaysia. We tried to treat him, though determining the right dosage remained a challenge. Nonetheless, we witnessed its effectiveness in halting the progression from pre-cancerous to full-blown metastasis. "I'm not claiming it cures cancer outright, but I personally witnessed its ability to impede the cancerous process before it fully developed," he said. Legislative review: Balancing law and medical advancements While the global landscape is shifting, Malaysia grapples with stringent laws, labeling cannabis possession as a punishable offense under the Dangerous Drugs Act of 1952. However, recent legislative amendments have shown promise, with the removal of the mandatory death penalty for certain offenses, including drug trafficking. Furthermore, the UN's reclassification of cannabis to acknowledge its therapeutic uses signifies a turning point in global perspectives. Evidential challenges Yet, the efficacy of medical cannabis in managing pain remains a subject of scrutiny. Studies, such as those referenced by CodeBlue in its article: Evidence Lacking On Medical Cannabis For Pain dated December 29, 2022 highlight the limited evidence supporting its effectiveness, with only a fraction of individuals experiencing a meaningful reduction in pain across clinical trials. This underscores the need for more robust, systematic research to establish the veritable benefits of cannabinoids in pain management. Australia's experience with medical cannabinoids sheds light on the challenges, where despite high demand, evidence supporting its efficacy remains elusive. The absence of subsidization underlines the need for rigorous assessment of both effectiveness and cost-effectiveness before integration into mainstream medical practices. Insights into Malaysian sentiments Malaysia's exploration into the potential of medical cannabis has sparked discussions and garnered substantial public support, as indicated by preliminary studies. However, the path toward acceptance and regulatory integration demands a delicate balance between scientific evidence, public opinion, and legislative reforms. In navigating this evolving landscape, Malaysia stands at a crossroads, contemplating the integration of medical cannabis and cannabinoids into its healthcare framework. The ongoing feasibility study, aiming to evaluate the market potential, coupled with the Health Ministry's openness to scientific advancements, sets the stage for a nuanced approach. As we tread this uncharted territory, fostering an environment conducive to rigorous research, clinical trials, and evidence-based practices becomes imperative. The journey toward embracing medical cannabis and cannabinoids as viable alternatives for pain management necessitates collaborative efforts, scientific rigor, and a commitment to unraveling their true therapeutic potential. The convergence of legislative reforms, evolving societal perceptions, and burgeoning scientific insights beckons Malaysia to embark on a journey toward a nuanced, evidence-based approach to integrate medical cannabis into its healthcare landscape. |
|
|
